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A B S T R A C T
The fastidious porcine respiratory pathogen Mycoplasma hyopneumoniae has proven difficult to culture
since it was first isolated in 1965. A reliable solid medium has been particularly challenging. Moreover,
clinical and pathological samples often contain the fast-growing M. hyorhinis which contaminates and
overgrows M. hyopneumoniae in primary culture. The aim of this study was to optimise the culture
medium for recovery of M. hyopneumoniae and to devise a medium for selection of M. hyopneumoniae
from clinical samples also containing M. hyorhinis. The solid medium devised by Niels Friis was improved
by use of Purified agar and incorporation of DEAE-dextran. Addition of glucose or neutralization of acidity
in liquid medium with NaOH did not improve the final yield of viable organisms or alter the timing of
peak viability. Analysis of the relative susceptibility of M. hyopneumoniae and M. hyorhinis strains to four
antimicrobials showed that M. hyopneumoniae is less susceptible than M. hyorhinis to kanamycin. This
was consistent in all UK and Danish strains tested. A concentration of 2 mg/ml of kanamycin selectively
inhibited the growth of all M. hyorhinis tested, while M. hyopneumoniae was able to grow. This forms the
basis of an effective selective culture medium for M. hyopneumoniae.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Mycoplasma hyopneumoniae is the primary cause of enzootic
pneumonia (EP) in pigs. The disease is of global significance both in
reducing growth efficiency and in promoting susceptibility to
concurrent bacterial and viral infections (Thacker et al., 1999).
Diagnosis of EP is usually by a combination of serological tests (Feld
et al., 1992; Djordjevic et al., 1994), PCR of nasal secretion or lung
tissue at slaughter (Mattsson et al., 1995; Baumeister et al., 1998;
Stemke, 1997), real-time PCR (Dubosson et al., 2004; Marois et al.,
2010) and isolation in culture (Kobisch and Friis, 1996). However,
M. hyopneumoniae is notoriously fastidious (Goodwin and Hurrell,
1970) and culture remains challenging and time consuming. The
most widely used liquid medium for culture of M. hyopneumoniae
was developed by Niels Friis (1975). Homogenised lung tissue was
serially diluted in tubes of the medium and incubation led to a
gradual colour change of the phenol red indicator from pink to* Corresponding author.
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However, individual mycoplasmas could only be purified by
terminal dilution in the liquid medium.
A commercial medium is available from Mycoplasma Experi-
ence1 Ltd. U.K. (ME). Both liquid and solid media are available.
These support the growth of M. hyopneumoniae but the constit-
uents of this commercial medium are not publicly available.
Solidification of Friis medium with Agar did not allow growth of
colonies of M. hyopneumoniae, suggesting that the agar was
inhibitory to growth or sequestered an essential nutrient. The use
of a better defined solid medium would allow greater flexibility for
research, such as transformation of M. hyopneumoniae (Maglennon
et al., 2013a).
When used for diagnostic purposes, both Friis medium and ME
media are easily overgrown by the faster-growing M. hyorhinis
which is sometimes present in pig lung lesions alongside
M. hyopneumoniae and frequently in apparently normal tissue
(Kobisch and Friis, 1996). To suppress the growth of M. hyorhinis,
Friis recommended the use of 5% hyperimmune anti-M. hyorhinis
rabbit serum and 500 mg/ml cycloserine (Friis, 1971). However,
such serum is not always available, is expensive, and batches of
serum vary in their capacity to suppress M. hyorhinis.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Viability and colour shift of M. hyopneumoniae cultured in Friis broth. Viable
cell counts were performed every 12 h and the colour shift recorded. Results are
from two independent determinations of the growth curve.
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medium for transformation and mutagenesis of M. hyopneumoniae,
allowing single colonies to be readily distinguished and selected,
and to devise an improved selection medium for the suppression of
M. hyorhinis.
2. Materials & methods
2.1. Mycoplasma strains
M. hyopneumoniae strains 277/94 and 325/95 were the gift of
Niels Friis, Danish Veterinary Institute, Copenhagen. Other strains
of M. hyopneumoniae were Danish field isolates from lesions of EP,
the gift of Dr Branko Kokotovic, Danish Veterinary Institute, or UK
field isolates from slaughterhouse lesions of EP. M. hyorhinis strains
were UK field isolates obtained from pig lungs with or without
gross lesions at post-mortem. The identity of all organisms was
confirmed using species-specific PCR amplifying a region of the
conserved hypothetical protein mhp165 from M. hyopneumoniae
(Baumeister et al., 1998) and the highly conserved 16S rRNA region
of M. hyorhinis (Lin et al., 2006). The identity of all
M. hyopneumoniae strains was subsequently confirmed by whole
genome sequencing and genome-wide analysis (J. Welch 
personal communication).
2.2. Liquid culture medium
Friis medium was prepared largely as described by Kobisch and
Friis (1996) with the following modifications: bacitracin and
meticillin were replaced with azlocillin and flucloxacillin (final
concentration 50 mg/ml). To make 500 ml of Friis medium, 1.5 g
Brain Heart Infusion (BHI) (Difco) and 1.6 g PPLO (Difco) was
dissolved in 365 ml water and sterilised by autoclaving. To this
were added 18 ml of yeast extract (prepared from dried bakers
yeast), 12.5 ml sterile solution A (160 g/l NaCl, 4 g/l; 8 g/l KCl, 2 g/l
MgSO47H2O, 2 g/l MgCl2.6H2O, 3.7 g/l CaCl22H2O), 12.5 ml sterile
solution B (3.0 g/l Na2HPO4.12H2O, 1.2 g/l KH2PO4), 50 ml pig serum
(Invitrogen) heat-treated at 56 C for 20 min, 50 ml heat-treated
horse serum (Invitrogen), 1 ml phenol red solution (0.6% in 0.1 M
NaOH), 25 ml of each of 100 mg/ml azlocillin and flucloxacillin and
adjusted to pH 7.4 with 1.0 M NaOH.
2.3. Solid culture medium
Concentrated (2.8) Friis medium was prepared by the addition
of 88 ml water to 4.3 g BHI, 4.6 g PPLO sterilised by autoclaving,
51.4 ml yeast extract, 35.7 ml sterile solution A, 35.7 ml sterile
solution B, 143 ml heat-treated horse serum, 143 ml heat-treated
pig serum, 2.8 ml 0.6% phenol red solution, azlocillin and
flucloxacillin (final concentration 140 mg/ml), pH 7.4. Friis agar
was prepared by mixing concentrated Friis medium (2.8), mixed
at a ratio of 35: 65 with either 1.8% agar No. 1 (Oxoid, L11), Purified
agar (Oxoid, L28) or agarose (Invitrogen). Where indicated, DEAE-
dextran (Sigma-Aldrich, Gillingham, UK) was added to agar at
0.1 mg/ml. Mycoplasma Experience1 solid medium was prepared
according to the manufacturer’s instructions (Mycoplasma Expe-
rience1 Ltd, Reigate, UK). Cultures were incubated in a humidified
incubator at 37 C in 5% CO2.
Charcoal-treated agar was prepared by incubating a 1.3%
solution of Bacteriological agar with 2% w/v of activated charcoal
(Oxoid, Basingstoke, UK) for 10 min at 55 C, the charcoal was then
removed using a sieve. Following sterilisation, each agar type was
mixed with medium supplement (Mycoplasma Experience Ltd,
UK) or concentrated Friis medium at a ratio of 35: 65 (supplement:
agar) and plates poured.2.4. Viability determination
Ten-fold serial dilutions in Hanks’ Balanced salts Solution
(HBSS; Life Technologies) were spotted (10 ml in triplicate) on to
solid medium. Cultures were incubated for 7 days in 5% CO2 at
37 C. Colonies were counted, from those dilutions showing the
largest number of separate colonies, using a dissecting micro-
scope; the triplicate counts were combined and the viability
calculated. Growth was also estimated from the metabolic activity
recorded as a colour shift of the phenol red pH indicator from pH
7.4 to 6.8 as described by Friis (1975).
2.5. Antibiotic susceptibility testing
Solutions of kanamycin (Sigma), tetracycline (Sigma) and
puromycin (Fisher) were prepared in de-ionised water. Chloram-
phenicol (Sigma) was dissolved in ethanol at 10 mg/ml final
concentration. All were sterilised through a 0.2 mm filter (Nalgene,
UK). A final antibiotic concentration range was achieved by two-
fold serial dilutions of each antibiotic in sterile water or ethanol as
appropriate. Antibiotics were incorporated into solid medium over
a range of concentrations 20–0.01 mg/ml (kanamycin), 4.0–
0.03 mg/ml (tetracycline), 20–0.06 mg/ml (chloramphenicol and
puromycin)
M. hyopneumoniae and M. hyorhinis inocula were prepared in 1 x
sterile phosphate buffered saline (BR0014G, Oxoid) as a suspension
containing approximately 103 CFU/ml. A sample of 10 ml of each
strain was inoculated onto each plate in triplicate. Plates were
incubated at 37 C with 5% CO2 and observed for growth of colonies
between day 2 and day 10. The MIC was determined as the highest
dilution of antibiotic giving an absence of growth as determined by
the formation of mycoplasma colonies.
3. Results
3.1. The relationship of viability and colour shift
The viability of M. hyopneumoniae to the commonly used colour
shift in liquid medium was determined (Fig. 1). Cultures reached a
maximum viability of 108.9 at approximately 2.5 days incubation.
This corresponded to a colour shift between 2 (pH 7.2) and 3 (pH
7.1). After this point there was an exponential decline reaching 106
CFU/ml after 8 days (beyond colour shift 4).
160 B.S. Cook et al. / Veterinary Microbiology 195 (2016) 158–1643.2. The effect of glucose and NaOH
The concentration of glucose in Friis medium is approximately
2 mM: 1 mM is derived from the brain heart infusion broth and
another 1 mM from the diluted serum. To investigate whether
glucose is limiting the growth, further glucose was supplemented
into the liquid medium to give 4 mM (2) and 8 mM (4) glucose,
and viable counts performed through the growth cycle. The growth
curve was unchanged by the increased glucose concentrations
(Fig. 2). Friis suggested that the decline in viability when yellow
colour shift was reached was due to the acidification of the
medium. If so, this might be prevented by addition of alkali to the
medium as the colour changes at the growth peak (60 h). Addition
of alkali to neutralize the pH caused a marginal improvement in
survival at 4–6 days although this difference was not marked
(Fig. 2).
3.3. Solidifying Friis medium
In order to use Friis medium as the base for a solid medium to
culture M. hyopneumoniae, different agar preparations were mixed
with Friis base and or Mycoplasma Experience1 (ME) supplement
and investigated for the ability to support the growth of M.
hyopneumoniae colonies. The results are shown in Table 1.
Friis medium solidified with the commercially supplied ME
agar grew colonies of M. hyopneumoniae 277/94 & 325/95. When
Agar no.1, used widely in the solidification of bacteriological
culture medium, was mixed with either Friis medium or ME
supplement there was no growth of M. hyopneumoniae. Pre-
treatment of the agar with activated charcoal, in an attempt to
remove any growth-inhibiting components, did not alter the
ability of medium made with either supplement to support M.
hyopneumoniae. However, when either Purified agar or agarose
were used as the solidifying agent, Friis medium, but not the ME
supplement, grew colonies of M. hyopneumoniae (Table 1).
ME solid medium supported the growth of M. hyorhinis. When
charcoal-treated agar, agarose or Purified agar were used, ME
supplement did not grow M. hyorhinis colonies while Friis medium
supported M. hyorhinis when solidified with each of the different
agars.Fig. 2. Effect of glucose and alkali on the growth curve of M. hyopneumoniae. Viable
counts were performed at intervals. Friis broth contained either 2 or 4 the
normal concentration of glucose. The culture (NaOH) was neutralized to pH 7.3 at
2.5 days post inoculation.Based on the findings of Tauraso (1967) and as noted by Friis
(1975) & Kobisch and Friis (1996), DEAE-dextran was added to the
agar while molten and the growth of two strains of
M. hyopneumoniae and M. hyorhinis were compared. Results are
shown in Table 1. The inclusion of DEAE-dextran into Purified agar
further enhanced the growth of colonies for strains of
M. hyopneumoniae (strains 277/94 and 325/95) and appeared to
be superior to the medium commercially available (Fig. 3).
3.4. Selective culture of M. hyopneumoniae
The susceptibility of M. hyopneumoniae 277/94 and 325/95, and
M. hyorhinis Mhr1/09 was measured on solid medium containing
four antimicrobials over a range of concentrations. The results are
shown in Table 2. The MIC of kanamycin for M. hyopneumoniae
isolates 325/95 and 277/94 was shown to be 8.0 mg/ml while
M. hyorhinis appeared to be susceptible to a lower concentration,
with an MIC of 1.0 mg/ml. Both strains of M. hyopneumoniae grew
on medium containing 6.5 mg/ml. A mixed culture (equal
numbers) of M. hyopneumoniae strain 277/94 and M. hyorhinis
Mhr1/09 was used to assess the ability of kanamycin to selectively
suppress the growth of M. hyorhinis on solid medium. After 8 days
incubation in the absence of kanamycin, M. hyorhinis colonies
outgrew M. hyopneumoniae as recognised by colony morphology
(Fig. 4A & B). However, with addition of 2 mg/ml kanamycin only
M. hyopneumoniae colonies appeared to grow (Fig. 4C & D).
The relative sensitivity of Mhr1/09 to kanamycin prompted the
testing of more strains. A further 19 M. hyopneumoniae and 12 M.
hyorhinis field isolates from the UK and Denmark, whose identity
was confirmed by both PCR and growth characteristics, were tested
for their susceptibility to kanamycin on MH selective medium
(Table 3). All M. hyopneumoniae isolates grew in the presence of
2 mg/ml kanamycin. The isolates appeared to be unaffected by the
incorporation of kanamycin into the medium with the exception of
isolate Mp258/94 in which a small amount of growth suppression
was noted in terms of colony size. The growth of all 12 M. hyorhinis
isolates was completely inhibited by the addition of kanamycin in
solid medium. Samples of pneumonic lung lesions were obtained
from the abattoir over a period of 12 months. Cultures of these
grown on MH selective medium were free from M. hyorhinis while
approximately 60% of samples grown on non-selective Friis liquid
and solid medium contained M. hyorhinis and became rapidly
overgrown (Table 3).
4. Discussion
M. hyopneumoniae has been long recognised as difficult and
unreliable to culture (Friis, 1971). Growth on solid medium has
been considered particularly difficult with colonies growing to
only 0.3–0.5 mm diameter in 7–10 days. This study was a
systematic investigation to improve the medium for culture of
this pathogen. The resulting improved medium was crucial in the
successful development of transformation and transposon muta-
genesis of M. hyopneumoniae as described by Maglennon et al.
(2013a,b).
Establishment of the growth curve for M. hyopneumoniae in
Friis medium was a pre-requisite for studies to allow efficient
transformation. Using viable counts on the solid medium
described here, rather than colour change units or the indirect
methods of colour shift (Friis, 1975) or measuring ATP by
luminometry (Stemke and Robertson, 1990; Calus et al., 2010),
the growth curve could be accurately determined.
It has been considered that glucose is the primary carbon and
energy source for M. hyopneumoniae. Supplementation of the
medium with additional glucose did not improve the viability or
growth rate. This was consistent with the results of Stemke and
Table 1
Growth of M. hyopneumoniae and M. hyorhinis on different solid media following 10 and 5 days incubation at 37 C.
Sample Liquid medium Test agar M. hyopneumoniae M. hyorhinis
1 ME supplement ME agar +++ +++
2 1.3% Agar No. 1. NG NG
3 Charcoal-treated No. 1 NG NG
4 1.3% agarose NG NG
5 1.3% Purified agar NG NG
6 Modified Friis (x2.8) ME agar +++ +++
7 1.3% Agar No. 1. NG +++
8 Charcoal-treated No. 1 NG +++
9 1.3% agarose +++ +++
10 1.3% Purified agar ++ +++
Fig. 3. Colonies of M. hyopneumoniae 325 on different solid media preparations. Colonies were incubated for 7 days at 37 C in a humidified box and photographed using a
dissecting microscope. A, ME supplement solidified with ME agar; B, modified Friis medium solidified with 0.85% Purified agar; C, modified Friis medium solidified with 0.8%
Purified agar and 0.1 mg/ml DEAE-dextran; D, modified Friis medium solidified with 0.9% agarose. Arrows indicate small M. hyopneumoniae colonies..
Table 2
MICs of antimicrobial agents for M. hyopneumoniae strain 277/94 and 325/95, and
M. hyorhinis Mhr1/09 for kanamycin, tetracycline, chloramphenicol and puromycin
determined on solid medium.
Antimicrobial agent MIC mg/ml
277/94 325/95 Mhr1/09
Kanamycin 8.0 8.0 1.0
Tetracycline 0.125 0.125 0.06
Chloramphenicol 2.5 2.5 2.5
Puromycin 1.25 1.25 2.5
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viability. They used 27 mM glucose. Since physiological glucose
concentrations are normally between 3 and 5 mM, we considered
an increase to 4 and 8 mM to be appropriate for the medium.Quenching of the acid formed in the medium using NaOH had only
a minor effect on the viability, which by 8 days incubation had
reached the level of the control without added NaOH. Thus it is
likely that depletion of key nutrients rather than acid inhibition is a
factor limiting growth in culture.
Initial experiments indicated that the purity of the agar used to
solidify modified Friis medium greatly affected the growth of
M. hyopneumoniae. Bacteriological agar was found to prevent the
growth of M. hyopneumoniae colonies. Gould et al. (1944) had
reported a similar inhibitory effect on the growth of Neisseria
gonorrhoeae following the solidification of liquid medium with
agar. Ley and Mueller (1946) identified a component, similar to a
fatty acid, present in agar following methanol extraction. This
extracted component present within agar was found to inhibit the
growth of N. gonorrhoeae in the absence of starch. Activated
charcoal is known to adsorb several impurities such as fatty acids.
Fig. 4. Suppression of M. hyorhinis growth following kanamycin selection on solid medium. Growth of a mixed mycoplasma culture containing 1:1 equal volumes of M.
hyopneumoniae and M. hyorhinis mid-log phase culture, following 9 days incubation on Friis solid medium with and without 2 mg/ml kanamycin at 37 C in a humidified box.
A, M. hyopneumoniae 277 and M. hyorhinis; B, M. hyopneumoniae 325 and M. hyorhinis; C, M. hyopneumoniae 277 and M. hyorhinis with 2 mg/ml kanamycin; D, M.
hyopneumoniae 277 and M. hyorhinis with 2 mg/ml kanamycin..
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factors from the agar such as free fatty acid-like inhibitors by
treatment with activated charcoal. Since activated charcoal had no
effect on the agar, we conclude that this was failure to remove
inhibitory factor(s).
When the commercial ME supplement was solidified with agar
other than the supplied agar component it was unable to support
the growth of either M. hyorhinis or M. hyopneumoniae. This
suggested that an essential constituent for growth was absent from
the liquid supplement and only present within the agar compo-
nent. Solidifying Friis medium with Purified agar treated with
DEAE-dextran confers a substantial improvement on the commer-
cially available medium for growth of M. hyopneumoniae. Since
DEAE is a positively charged group able to bind negatively charged
ions, its action may be explained by chelation of the agaropectin
present in agar which may be inhibitory to growth of M.
hyopneumoniae. Agaropectin is the mixture of smaller molecules,
comprising alternating residues of L- and D-galactose modified
with acidic side-groups (particularly sulfate). This is consistent
with the beneficial use of purified agarose, which is depleted of
agaropectin, over agar no. 1 in this study. No equivalent
improvement was seen from DEAE in culture of M. hyorhinis,
suggesting that it is less sensitive to the acidic components of
agaropectin.
Friis (1971) described a selective medium to suppress M.
hyorhinis. This requires rabbit antiserum which is expensive andnot always available for regular culture. In testing the relative
sensitivity of M. hyopneumoniae and M. hyorhinis to four
antimicrobials, our results showed that the latter was consistently
more sensitive to kanamycin. Williams (1978) had previously
shown that both M. hyorhinis and M. hyopneumoniae were
susceptible to kanamycin (0.1 and 0.5 mg/ml respectively).
However, different isolates were used, and determination of the
MIC by Williams was in liquid medium. Nevertheless, incorpo-
ration of 2 mg/ml of kanamycin into the agar medium appeared to
prevent the growth of M. hyorhinis following 8 days incubation.
When mixed in equal volumes with M. hyopneumoniae strain 325,
the M. hyorhinis did not form colonies while controls, without the
addition of kanamycin, yielded only M. hyorhinis colonies from the
mixed culture. Screening of M. hyopneumoniae and M. hyorhinis
strains showed that this difference in kanamycin susceptibility was
present between all M. hyopneumoniae and M. hyorhinis strains
tested.
The addition of kanamycin can be used in place of the
hyperimmune rabbit serum and gives a clean selection for the
culture of M. hyopneumoniae, effectively preventing the growth of
M. hyorhinis while allowing colonies of M. hyopneumoniae to form.
The relative kanamycin resistance of M. hyopneumoniae has greatly
improved the primary isolation of M. hyopneumoniae from abattoir
tissue samples originating from 15 different farms. False negatives,
resulting from M. hyorhinis overgrowth have been overcome using
this selective medium.
Table 3
Growth of M. hyopneumoniae and M. hyorhinis isolates on solid medium with and without 2 mg/ml kanamycin.
M. hyopneumoniae isolate Source Growth on solid medium
No kanamycin 2 mg/ml kanamycin
MH001 UK field isolates from lung lesions 2009–2010 +++ ++
MH002 +++ +++
MH003 +++ +++
MH005 +++ +++
MH008 +++ +++
MH010 +++ +++
MH011 +++ +++
MH015 +++ ++
MH016 +++ +++
MH031 +++ +++
MH033 +++ +++
MS2 Danish field isolates from lung lesions 1969 +++ +++
MS3 +++ +++
MS8 +++ +++
MS13 +++ +++
MS15 +++ +++
MS25 +++ +++
MS29 +++ +++
Mp258/94 Danish field isolates from lung lesions 1994–2007. +++ +
Mp277/94 ++ ++
Mp473/95 + +
Mp738/95 +++ +++
Mp325/95 ++ ++
Mp79/06 +++ ++
Mp87/06 ++ +
Mp92/06 +++ +++
Mp96//06 +++ +++
Mp85/07 + +
Mp261/07 +++ +++
M. hyorhinis isolate Source Growth on solid medium
No kanamycin 2 mg/ml kanamycin
MHR01 UK field isolates from lung lesions 2009–2010. +++ NG
MHR02 +++ NG
MHR04 +++ NG
MHR05 +++ NG
MHR06 +++ NG
MHR07 +++ NG
MHR08 +++ NG
MHR09 +++ NG
MHR10 +++ NG
MHR11 +++ NG
MHR12 +++ NG
P450 +++ NG
+++ large colonies; ++ medium colonies; + small colonies; NG = no colonies formed.
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